Skip to main content
. 2024 Sep 30;15(9):704. doi: 10.1038/s41419-024-07082-x

Fig. 4. Cholesterol inhibition enhances the antitumor activity of gilteritinib in lung cancer cells.

Fig. 4

A The effect of ABCA1 overexpression on cell proliferation in gilteritinib-treated A549 and H1650 cells. B The prognostic value of ABCA1 in lung cancer patients was analyzed using the Kaplan–Meier Plotter. C A549 cells were treated with 100 nM gilteritinib alone, or 2.5 μM NB-598 alone, or in combination, intracellular free cholesterol was visualized using filipin staining. D A549 and H1650 cells were treated with 100 nM gilteritinib alone, or 2.5 μM NB-598 alone, or in combination, cell vitality was determined using crystal violet staining. E A549 and H1650 cells were treated with the indicated agents, apoptosis was measured by flow cytometry. F A549 and H1650 cells were treated with increasing concentrations of gilteritinib alone or in combination with 2.5 μM NB-598, and cell vitality was determined by CCK8 assay. G The prognostic value of SQLE in lung cancer patients was assessed by the Kaplan–Meier survival analysis. H Intracellular free cholesterol in parental and gilteritinib-resistant A549 and H1650 cells was labeled using filipin staining. I Gilteritinib-resistant or parental A549 cells were treated by 3 μM NB-598, and viability was measured using crystal violet staining. ***P < 0.001.